My list of publications includes over 20 peer-reviewed scientific articles. One of them is a special one because the Finnish Current Care Guidelines mention it for heart failure. This blog discusses the impact of research by Medaffcon on treatment practices.
A study published in January 2024 in the Scandinavian Journal of Gastroenterology has revealed that the treatment of adults with Short Bowel Syndrome (SBS-IF) clearly has significant room for improvement. Patients require extensive amounts of healthcare services, and their mortality rate is elevated.
Our latest multiple myeloma publication describes how complex multiple myeloma treatment patterns were assembled from data available in the Helsinki University Hospital data lake, Finland, how the treatments have changed in 2013–2019, and what the estimated treatment costs are in multiple myeloma.The study published online in October 2023 was carried out by the experts at Medaffcon Oy, Sanofi Oy, and Helsinki University Hospital, Finland.
Utilising the data lake of the Hospital District of Southwest Finland (TYKS), Medaffcon, Pfizer and TYKS have examined the clinical adoption of new medications for advanced renal cell carcinoma and the utility of data extracted without extensive manual extraction.
Hospital data lakes are a central source of information in Medaffcon's studies, and often, data retrieval can be automated. However, what happens when more complex matters need to be extracted from the databases? In such cases, manual extraction is used, says Medaffcon's Scientific Advisor, Riikka Mattila
Real-world data (RWD) can, however, be utilised also in a variety of non-clinical medical and pharmaceutical studies to compare aspects such as treatment outcomes and resource utilisation between different geographies and treatment options, reminds Samuli Tuominen, senior data scientist at Medaffcon.
Coming up soon, Copenhagen will be the center of health economics as more than five thousand pharmaceutical and healthcare professionals gather for the ISPOR conference. ISPOR has been well known, especially among health economists. However, this years’ top trends real-world data (RWD) and real-world evidence (RWE) attract even wider audience.
AstraZeneca Finland, Medaffcon and clinical experts have investigated what is the rarer endotype of severe asthma using biomarker data obtained from the data lake of Turku University Hospital (TYKS), Auria.
Samuli Tuominen, senior data scientist at Medaffcon, has co-authored a study that utilised propensity-score matching to compare the performance of two immunosuppressive drugs in patients with primary sclerosing cholangitis after liver transplantation. Medaffcon has helped to validate the superiority of tacrolimus over cyclosporine as a post-liver transplantation immunosuppressive regimen for patients with primary sclerosing cholangitis, a rare immune-mediated cholestatic liver disease.
Experts at Medaffcon have perused volumes of real-world data on patients with atopic dermatitis to provide new insights into co-morbidities and treatment patterns associated with the chronic skin condition.
Experts from Medaffcon, Takeda and the Hospital District of Helsinki and Uusimaa (HUS) have concluded an extensive study into paediatric short-bowel syndrome based on information from patient records.
Our first national multiregister study on sexually transmitted diseases provides important information on the burden of genital warts (GWs) in Finland.
Studies mapping short-term absences provide new information on the burden caused by diseases for healthcare services and the society.
Register study undisputedly confirms that a smoker’s risk for any postoperative complications is significantly higher than non-smokers’.
The result of a recent original study surprised the researchers: the costs of treating heart failure tenfold in exacerbation. The results were published in Duodecim on 23 March 2023.
In this nationwide register study, we described the incidence, prevalence, and treatment burden of chronic rhinosinusitis with nasal polyps (CRSwNP), and its disease association with asthma from 2012 to 2018 in Finland.
Our recent RWE study detailed the comorbidity burden of Finnish multiple myeloma (MM) patients diagnosed between 2005 and 2016.
The study assessed the prevalence of Gaucher disease in Finland and developed methods to screen...
Chronic kidney disease has been suggested as the main contributor to the increased cardiovascular morbidity...
Cardiovascular diseases are the leading cause of disability and premature death worldwide. Real-world evidence (RWE)...
Real-world data on diffuse large B-cell lymphoma (DLBCL) has remained incomplete. In Finland, electronic health...
Research has shown that osteoarthritis causes disability, especially among older adults. Our latest real-world evidence...
Multiple myeloma (MM) is a hematologic cancer displaying an abnormal heterogenous B cell population in...
A prototype of a Gaucher disease point-scoring system (PSS), originally established by the Gaucher Earlier...
Migraine is a disabling headache disorder that places a significant burden both for the patients...
The proportion of patients hospitalized for heart failure (HF) with preserved left ventricular ejection fraction...
In migraine, co-occurrence of two or more diseases or conditions is typical. Asthma and allergies,...
A new real world evidence study on Idiopathic pulmonary fibrosis (IPF) describes the high disease...
Chronic obstructive pulmonary disease is one of the leading causes of mortality and morbidity worldwide....
The Burden of Migraine Study continues The study ‘Migraine comorbidity and phenotypic disease networks in...
Medaffcon’s new real-world evidence study on the burden of adult asthma in Finland demonstrates the...
The high mortality rate of heart failure (HF) patients compared to age-matched controls highlights the...
New real-world evidence (RWE) based study shows that migraine nearly doubles the amount of healthcare...